Successful treatment with atomoxetine of an adolescent boy with attention deficit/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function

Obes Facts. 2013;6(1):109-15. doi: 10.1159/000348792. Epub 2013 Mar 6.

Abstract

Objective: Recent case reports suggest a link between reduced melanocortinergic tone and both obesity and attention deficit / hyperactivity disorder (ADHD). We present the case of a 13-year-old, male, obese MC4R mutation carrier with ADHD.

Case report: The boy carries a heterozygous mutation in the melanocortin 4 receptor gene (MC4R; Met281Val), that leads to a reduced receptor function. Dominant mutations of this type represent major gene effects for obesity. He participated in a lifestyle intervention program for obesity and received treatment with the selective norepinephrine re-uptake inhibitor atomoxetine for 31 months. The boy markedly reduced his BMI from 47.2 to 29.6 kg/m².

Conclusion: Atomoxetine proved to efficiently reduce weight in a severely obese MC4R mutation carrier with ADHD. We briefly discuss possible mechanisms for our observation, including evidence for the functional connectivity between melanocortinergic, dopaminergic, and norepinephrinergic brain circuitries.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenergic Uptake Inhibitors / therapeutic use*
  • Atomoxetine Hydrochloride
  • Attention Deficit Disorder with Hyperactivity / complications
  • Attention Deficit Disorder with Hyperactivity / diagnosis
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / genetics
  • Attention Deficit Disorder with Hyperactivity / metabolism
  • DNA Mutational Analysis
  • Genetic Predisposition to Disease
  • Humans
  • Male
  • Mutation
  • Obesity / complications
  • Obesity / diagnosis
  • Obesity / drug therapy*
  • Obesity / genetics
  • Obesity / metabolism
  • Phenotype
  • Propylamines / therapeutic use*
  • Receptor, Melanocortin, Type 4 / genetics
  • Receptor, Melanocortin, Type 4 / metabolism*
  • Risk Reduction Behavior
  • Treatment Outcome
  • Weight Loss / drug effects

Substances

  • Adrenergic Uptake Inhibitors
  • MC4R protein, human
  • Propylamines
  • Receptor, Melanocortin, Type 4
  • Atomoxetine Hydrochloride